TY - JOUR
T1 - A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex
T2 - AIDS clinical trial group 393 study team
AU - Aberg, Judith A.
AU - Williams, Paige L.
AU - Liu, Tun
AU - Lederman, Howard M.
AU - Hafner, Richard
AU - Torriani, Francesca J.
AU - Lennox, Jeffrey L.
AU - Dube, Michael P.
AU - MacGregor, Rob Roy
AU - Currier, Judith S.
AU - Nevin, Thomas
AU - Zhou, Yinmei
AU - Owens, Susan
AU - Hojczyk, Peter
AU - Conklin, Michael
AU - Wallis, Robert S.
AU - Inderlied, Clark
AU - Purdue, Lynette
AU - McFeely, John
AU - Laverty, Maura
AU - Ortiz, Olivia
AU - Thompson, James Bryan
AU - Wiggins, Ilene
AU - Craft, Jean
AU - Goldman, Mitchell
AU - Colletti, Mary Ann
AU - Sha, Beverly
AU - Arri, Carol
AU - Slamowit, Debbie
AU - Lee, Stephen
AU - Santangelo, Joanne
AU - Canmann, Sally
AU - Johnson, Steven
AU - Ogata-Arakaki, Debra
AU - Shiramizu, Bruce
AU - Frarey, Laurie
AU - Van Der Horst, Charles
AU - Shank, Doris
AU - Canchola, Frances
N1 - Funding Information:
Financial support: National Institutes of Allergy and Infectious Disease (AIDS clinical trials grant AI38858); General Clinical Research Center Units, funded by the National Center for Research Resources; Emory University (AIDS Clinical Trials Unit [ACTU] grant AI32775); Johns Hopkins University (ACTU grant AI27668 and Genral Clinical Research Center [GCRC] grant RR-00052); San Francisco General Hospital (GCRC grant RR-00083); University of California, San Diego (ACTU grant AI 27670); University of North Carolina (ACTU grant AI25868 and GCRC grant RR00046).
PY - 2003/4/1
Y1 - 2003/4/1
N2 - The present nonrandomized prospective study evaluated whether antimycobacterial therapy for disseminated Mycobacterium avium complex (MAC) could be withdrawn from human immunodeficiency virus-infected subjects who experienced immunologic recovery while receiving highly active antiretroviral therapy (HAART). Eligible subjects had received macrolide-based therapy for least 12 months, were asymptomatic for MAC, had received HAART for at least 16 weeks, and had CD4+ T cell counts >100 cells/μL. Forty-eight subjects were enrolled, with a median CD4+ T cell count of 240 cells/μL at the time of discontinuation of MAC therapy. Forty-seven subjects remained MAC free, whereas 1 subject developed localized MAC osteomyelitis. The median duration of follow-up while not receiving therapy was 77 weeks, and the incidence of MAC infection was 1.44/100 person-years (95% confidence interval, 0.04-8.01). Withdrawal of anti-MAC therapy appears to be safe in patients who have been treated with a macrolide-based regimen for at least 1 year and have an immunologic response on HAART.
AB - The present nonrandomized prospective study evaluated whether antimycobacterial therapy for disseminated Mycobacterium avium complex (MAC) could be withdrawn from human immunodeficiency virus-infected subjects who experienced immunologic recovery while receiving highly active antiretroviral therapy (HAART). Eligible subjects had received macrolide-based therapy for least 12 months, were asymptomatic for MAC, had received HAART for at least 16 weeks, and had CD4+ T cell counts >100 cells/μL. Forty-eight subjects were enrolled, with a median CD4+ T cell count of 240 cells/μL at the time of discontinuation of MAC therapy. Forty-seven subjects remained MAC free, whereas 1 subject developed localized MAC osteomyelitis. The median duration of follow-up while not receiving therapy was 77 weeks, and the incidence of MAC infection was 1.44/100 person-years (95% confidence interval, 0.04-8.01). Withdrawal of anti-MAC therapy appears to be safe in patients who have been treated with a macrolide-based regimen for at least 1 year and have an immunologic response on HAART.
UR - http://www.scopus.com/inward/record.url?scp=0037383564&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037383564&partnerID=8YFLogxK
U2 - 10.1086/368413
DO - 10.1086/368413
M3 - Article
C2 - 12660918
AN - SCOPUS:0037383564
SN - 0022-1899
VL - 187
SP - 1046
EP - 1052
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 7
ER -